According to The Insight Partners' research, the North America Biopharmaceutical Contract Manufacturing Market was valued at US$ 16,488.3 Million in 2024 and is expected to reach US$ 41,018.6 Million by 2031, registering a CAGR of 14.0% from 2025 to 2031.
Advanced manufacturing technologies and rising demand for biologics are among the critical factors attributed to driving the North America biopharmaceutical contract manufacturing market growth.
Monoclonal antibodies, gene therapies, and cell-based treatments have created the need for more innovative, streamlined manufacturing processes. As a result, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies such as continuous manufacturing, automation, artificial intelligence (AI), and process analytical technologies (PAT) to enhance production capabilities and meet the growing demand for biopharmaceuticals. Continuous manufacturing is rapidly gaining traction in the biopharmaceutical industry as it allows the uninterrupted production of biologics, providing greater consistency, speed, and efficiency. This process reduces downtime between production runs and minimizes the need for intermediate storage, significantly reducing the production costs. According to a Baker McKenzie report, continuous manufacturing can reduce the cost of biological production by 30%. Novartis and Pfizer are among the major companies implementing continuous manufacturing for large-scale biologic production, demonstrating its effectiveness in improving operational efficiency and reducing costs. Additionally, the use of automated systems for activities such as cell culture monitoring, chromatography, and aseptic filling not only speeds up the manufacturing process but also reduces human error, enhances reproducibility, and ensures higher quality control. Automation also helps meet regulatory requirements by maintaining precise records and tracking each stage of the production process. For instance, Samsung Biologics has invested heavily in automation at its manufacturing facilities to streamline production and improve product quality. By incorporating automated systems, Samsung Biologics has been able to offer clients faster turnaround times and more reliable production capabilities. Artificial intelligence (AI) can also be used for process optimization, predictive maintenance, and quality control. AI-based tools can analyze vast amounts of production data in real-time, identifying potential issues before they arise and ensuring optimal conditions throughout the production process. This technology enables CMOs to minimize downtime and enhance yield rates. Companies such as Cognizant are already using AI to predict potential failures in manufacturing processes and improve decision-making.
Furthermore, process analytical technologies (PAT) are enabling real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By integrating PAT, manufacturers can detect variations early in the production process and adjust in real-time to prevent defects or inconsistencies. This results in higher-quality products and more efficient use of resources, reducing both time and cost. Therefore, the increasing adoption of advanced manufacturing technologies such as continuous manufacturing, automation, AI, and PAT is expected to contribute to the growth of the biopharmaceutical contract manufacturing market in the coming years.
On the contrary, the tightened budget and economic uncertainty hamper the growth of the North America biopharmaceutical contract manufacturing market.
North America Biopharmaceutical Contract Manufacturing Market Segmentation Analysis:
- By Product Type, the North America Biopharmaceutical Contract Manufacturing Market is segmented into Biologics and Biosimilar. The Biologics segment is projected to expand at 14.1% CAGR during 2025 - 2031.
- By Source, the North America Biopharmaceutical Contract Manufacturing Market is segmented into Microbial and Mammalian. The Microbial segment is projected to expand at 14.3% CAGR during 2025 - 2031.
- By Application, the North America Biopharmaceutical Contract Manufacturing Market is segmented into Commercial and Clinical. The Commercial segment is projected to expand at 14.5% CAGR during 2025 - 2031.
- By Therapeutic Area, the North America Biopharmaceutical Contract Manufacturing Market is segmented into Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others. The Oncology segment is projected to expand at 14.7% CAGR during 2025 - 2031.
By country, the North America Biopharmaceutical Contract Manufacturing Market is categorized into the United States, Canada, and Mexico. The United States is projected to expand at 14.1% CAGR during 2025 - 2031.
Key players operating in the Biopharmaceutical Contract Manufacturing Market are Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co Ltd, WuXi Biologics Inc, Merck KGaA, Ajinomoto Co Inc, Cytiva, and AGC Biologics AS, among others.
- In 2025, Samsung Biologics launched a new high-concentration formulation platform to support the development and manufacturing of high-dose biopharmaceuticals. S-HiCon can proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery. Through optimization of pH, buffer species, and excipients, along with a preliminary 'Concentration Gate Check' process, the platform tests formulation feasibility in the initial stages to identify favorable candidates and minimize potential risks associated with high concentration development.
- In 2024, Merck, a leading science and technology company, today announced a 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the company's contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com